: Our overall objective is to provide safe, effective, practical family-centered and integrated prevention, treatment and cure for HIV, TB and other comorbidities in individuals of all races, ages and gender, continuously refined through quality research, innovation and implementation. HIV/AIDS and TB are major global public health problems. South Africa has the highest population prevalence of HIV infection globally and the highest incidence in the world, with >60% of TB cases also HIV-infected. The SUN-CTU is located at the Faculty of Medicine and Health Sciences in urban Cape Town, Western Cape Province of South Africa, an epicenter of these twin epidemics, serving a population of approximately 2.5 million. SUN-CTU combines excellence in research and clinical care with a high prevalence of HIV and TB and populations accessed through 3 closely linked Clinical Research Sites (CRSs) with complementary research focus, strategically situated satellites and proven capacity for a broad spectrum of research. SUN-CTU has a strong family-centered approach, focusing on HIV- and TB-related research and care to large at-risk populations, spanning low birth weight and premature neonates, infants, children, adolescents and adults of all ages. The proposed well-integrated SUN-CTU is a pluripotent network expansion of an existing smaller CTU, at the Children's Infectious Diseases Clinical Research Unit (KID-CRU), focused on IMPAACT network activities. SUN-CTU has already demonstrated considerable capacity to conduct multiple clinical research projects through NIAID and other funding sources, and is particularly well aligned for participation in the IMPAACT, ACTG and HPTN networks.
South Africa-has a high population prevalence of HIV and TB infection, with >60% of TB cases also HIV infected. The SUN-CTU comprises 3 pluripotent CRSs with complementary research focus and a strong family-centered approach, focusing on HIV- and TB-related research and care to large at-risk populations, spanning low birth weight and premature neonates, infants, children, adolescents and adults of all ages.
|Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022|
|Seddon, J A; Weld, E D; Schaaf, H S et al. (2018) Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done? Int J Tuberc Lung Dis 22:24-33|
|Cranmer, Lisa M; Draper, Heather R; Mandalakas, Anna M et al. (2018) High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial. Pediatr Infect Dis J 37:e254-e256|
|Byabene, A K; Fortes-Déguénonvo, L; Niang, K et al. (2017) Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal. Trop Med Int Health 22:776-782|
|Nachega, Jean B; Uthman, Olalekan A; Mofenson, Lynne M et al. (2017) Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr 76:1-12|
|Innes, Steve; van Toorn, Ronald; Otwombe, Kennedy et al. (2017) Late-Onset Hiv Encephalopathy In Children With Long-Standing Virologic Suppression Followed By Slow Spontaneous Recovery Despite no Change In Antiretroviral Therapy: 4 Case Reports. Pediatr Infect Dis J 36:e264-e267|
|Nachega, Jean B; Adetokunboh, Olatunji; Uthman, Olalekan A et al. (2016) Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Curr HIV/AIDS Rep 13:241-55|
|Nachega, Jean B; Skinner, Donald; Jennings, Larissa et al. (2016) Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Prefer Adherence 10:683-90|
|Zachor, Hadas; Machekano, Rhoderick; Estrella, Michelle M et al. (2016) Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. AIDS 30:1221-8|
|Maritz, E R; Montepiedra, G; Liu, L et al. (2016) Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study. Int J Tuberc Lung Dis 20:1060-4|
Showing the most recent 10 out of 25 publications